Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Biliary tract cancers (BTCs) account for <1% of all human cancers. Cholangiocarcinoma (CCA) is the second most common primary liver cancer after hepatocellular carcinoma (HCC), accounting for ∼10%-15% of all primary liver cancers.1 The global mortality rate for CCA has increased worldwide during recent decades according to World Health Organization and Pan American Health Organization databases for 32 selected locations in Europe, America, Asia and Oceania. …
Continua a leggere

FGFR2 Inhibition in Cholangiocarcinoma

Biliary tract cancer (BTC) is the second most common primary liver cancer after hepatocellular carcinoma and accounts for 2% of cancer-related deaths. BTCs are classified according to their anatomical origin into intrahepatic (iCCA), perihilar, or distal cholangiocarcinoma, as well as gall bladder carcinoma. While the mutational profiles in these anatomical BTC subtypes overlap to a large extent, iCCA is notable for the high frequency of IDH1/2 mutations (10-22%) and the nearly exclusive …
Continua a leggere

Treatment of Intrahepatic Cholangiocarcinoma – A Multidisciplinary Approach

Intrahepatic cholangiocarcinoma (iCC) is distinguished as an entity from perihilar and distal cholangiocarcinoma and gallbladder carcinoma. Recently, molecular profiling and histopathological features have allowed further classification. Due to the frequent delay in diagnosis, the prognosis for iCC remains poor despite major technical advances and multimodal therapeutic approaches. Liver resection represents the therapeutic backbone and only curative treatment option …
Continua a leggere

Next-generation sequencing analysis of cholangiocarcinoma identifies distinct IDH1-mutated clusters

IDH1-mutated intrahepatic cholangiocarcinomas (IDH1m iCCAs) could be treated with anti-IDH1 drugs, although the high heterogeneity in this class of tumours could limit treatment efficacy. We selected 125 IDH1m iCCAs that were treated as resectable, locally advanced, or metastatic and were screened by the NGS-based FoundationOne gene panel. We conducted a mutation-based clustering of tumours and survival analysis. …
Continua a leggere

Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing

Cholangiocarcinoma (CCA) is a primary malignancy of the biliary tract with a dismal prognosis. Recently, several actionable genetic aberrations were identified with significant enrichment in intrahepatic CCA, including FGFR2 gene fusions with a prevalence of 10-15%. Recent clinical data demonstrate that these fusions are druggable in a second-line setting in advanced/metastatic disease and the efficacy in earlier lines of therapy is being evaluated in ongoing clinical trials …
Continua a leggere

Per maggiori approfondimenti visita il sito: colangiocarcinoma.net

La multidisciplinarietà per il paziente oncologico: l’importanza del confronto nell’approccio pratico
FAD, 1° maggio – 31 dicembre 2022

L’adroterapia e l’importanza della multidisciplinarietà per una terapia personalizzata
FAD, 1° luglio 2022 – 31 dicembre 2022

AIOM con i medici in formazione
Modena, 13 dicembre 2022

RadioLigand Therapy (RLT): la nuova frontiera dell’oncologia di precisione
I mercoledì dell’oncologia
Webinar, 14 dicembre 2022

GRANDANGOLO 2022
Genova e online, 15 – 16 dicembre 2022

Oncogeriatria verso il futuro
Padova, 15 – 16 dicembre 2022

4th BACK FROM INTERNATIONAL CONGRESSES & HOT TOPICS IN ONCOLOGY 2022
Monza, 20 dicembre 2022